TREATMENT STRATEGIES & ANTIVIRAL DRUG RESISTANCE

16TH EUROPEAN MEETING ON HIV & HEPATITIS

ROME, ITALY • 30 MAY - 1 JUNE 2018

MEETING PROSPECTUS
ADVANCING HEALTH GLOBALLY THROUGH NOVATIVE PROGRAMS DESIGNED FOR THE HEALTHCARE PROFESSIONAL
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome</td>
<td>4</td>
</tr>
<tr>
<td>Meeting description</td>
<td>5</td>
</tr>
<tr>
<td>Needs assessment</td>
<td>5</td>
</tr>
<tr>
<td>Target audience</td>
<td>5</td>
</tr>
<tr>
<td>Unique meeting features</td>
<td>5</td>
</tr>
<tr>
<td>Meeting objectives</td>
<td>6</td>
</tr>
<tr>
<td>Learning outcomes/ Impact</td>
<td>6</td>
</tr>
<tr>
<td>Assessment method</td>
<td>6</td>
</tr>
<tr>
<td>Accreditation</td>
<td>6</td>
</tr>
<tr>
<td>Infographics</td>
<td>7</td>
</tr>
<tr>
<td>Conference participation grants</td>
<td>8</td>
</tr>
<tr>
<td>Enduring materials</td>
<td>8</td>
</tr>
<tr>
<td>Committees</td>
<td>9</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>12</td>
</tr>
</tbody>
</table>

#EUHIV&HEP2018
Dear Colleague,

We are proud to announce the 16th edition of the European Meeting on HIV & Hepatitis - Treatment strategies & Antiviral Drug Resistance, to be held on 30 May - 1 June 2018 in Rome, Italy.

This meeting was first held 15 years ago with the objective to provide clinical virologists and other specialists treating infectious diseases who are involved in both research and clinical practice with the opportunity to share data and discuss their clinical application. At the time, the focus of the workshop was specifically on HIV antiretroviral drug resistance, which was the main challenge facing the clinician a decade ago. Hence the original name as the European Drug Resistance workshop.

By attending this meeting, you will receive a full overview of the latest developments in Hepatitis B, C and HIV, translated to clinical practice. The meeting will provide ample time for Q & A, discussion and interaction in a balanced and neutral scientific environment. Furthermore, much attention will be given to clinical management through extensive clinical case discussions.

#EUHIV&HEP2018
MEETING DESCRIPTION

DESCRIPTION AND NEEDS STATEMENT

The European Meeting on HIV & Hepatitis is the premier European platform for clinicians, allied healthcare providers, researchers and clinical virologists to discuss the latest developments in antiviral therapy for HIV, HCV and HBV and for translating them into new treatment strategies to further improve clinical care.

Founded fifteen years ago as the European HIV resistance workshop, the meeting evolved over the years to embrace all aspects of clinical care of people living with HIV in Europe. Particular emphasis is put on optimal treatment strategies, clinical virology, molecular epidemiology and public health aspects of HIV, HBV and HCV infections throughout Europe.

In the last decade the meeting has been able to engage leading clinicians and researchers from the different regions of Europe. As such, this meeting is the only European platform where HIV treating physicians and clinical virologists get together on an annual basis to present their latest research results and discuss their clinical implications in detail. The workshop has put a special emphasis on training young clinicians and scientists through clinical case discussions and parallel courses in collaboration with the European Society for Antiviral Research (ESAR).

UNIQUE MEETING FEATURES

• This program has become the PREMIER European platform for HIV clinicians, scientists and clinical virologists to discuss the latest developments affecting clinical practice.

• The meeting attracts a heterogeneous group of healthcare providers and scientists from the different regions of Europe.

• The meeting stimulates pan-European collaborations and networks.

• The workshop stimulates updates on guidelines and encourages treatment efficiency.

• The workshop provides grants to young researchers.

TARGET AUDIENCE

• clinicians involved in the daily care of individuals infected with HIV, HCV and HBV

• scientists involved in antiviral drug development, clinical virology and public health issues

• researchers

• post-graduate students
MEETING OBJECTIVES

• to gather professionals in the fields of HIV and Hepatitis clinical care and research in an interactive workshop setting
• to provide a platform for presentation and discussion of the latest developments in the field of antiviral drug development
• to map all current studies and results
• to translate new data to treatment guidelines
• to educate clinicians on how to best implement current and new drugs in clinical practice

LEARNING OUTCOMES/ IMPACT

After attending this meeting, participants will:

• have a thorough knowledge of the most recent results in drug development (including most recent clinical trials results) for HIV, HCV and HBV
• be able to integrate the latest scientific results into daily clinical care to improve the quality of life of HIV / Hepatitis infected individuals
• recognize future challenges in screening, monitoring and diagnosis of HIV and of HCV or HBV infected patients and develop new concepts for research and care strategies

ASSESSMENT METHOD

To assess the meeting, Virology Education provides each delegate with a detailed feedback form where they can assess the speakers, whether or not the meeting objectives were met, their intent to change, the rationale behind their motivation to attend, the general logistics of the meeting, and much more.

All their answers are then fully analyzed and a comprehensive report is created, to be shared with the committee members. These reports help us better understand our delegates and how to improve the next meeting.

For a maximum response rate, we invite the chairs of each session to encourage the participants to take a few minutes and complete the feedback forms. We are also introducing a web-based application to allow participants access to the feedback forms electronically.

ACCREDITATION

We plan to make an application to the EACCME® for CME accreditation of this event.
MEETING STATISTICS 2017

COUNTRIES
Over 300 participants from 39 countries attended the meeting in 2017.
Largest groups:
Italy: > 80
France: 27
Germany: 17
Poland, Belgium: 14

WORKPLACE TYPE
The majority of the > 300 delegates attending the European Meeting on HIV & Hepatitis were employed by a university (48%). Others were employed by a hospital (28%), industry (6%), Government (5%), or others.

RETURNING PARTICIPANTS
61% of participants attended both this one and one of the previous editions of the meeting.

LEARNING OBJECTIVES
Below is indicated to what extent participants indicated that the learning objectives were met.

<table>
<thead>
<tr>
<th></th>
<th>[Strongly] Agree</th>
<th>Neutral</th>
<th>[Strongly] Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>After attending this meeting, participants will:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Have a thorough knowledge of the most recent results in drug development (including most recent clinical trials results) for HIV, HCV and HBV</td>
<td>92%</td>
<td>8%</td>
<td>0%</td>
</tr>
<tr>
<td>Be able to integrate the latest scientific results into daily clinical care to improve the quality of life of HIV / Hepatitis infected individuals</td>
<td>83%</td>
<td>17%</td>
<td>0%</td>
</tr>
<tr>
<td>Recognize the future challenges in screening, monitoring and diagnosis of HIV and of HCV or HBV infected patients and develop new concepts for research and care strategies</td>
<td>92%</td>
<td>8%</td>
<td>0%</td>
</tr>
</tbody>
</table>
CONFERENCE PARTICIPATION GRANTS

The conference participation grants provide healthcare professionals with the opportunity to attend a conference they would otherwise be unable to attend due to financial restrictions. All applications include a CV, a motivation letter, and potentially an abstract (requirements vary depending on the workshop). These are submitted via an independent CPG portal and are evaluated against the assessment criteria using robust, impartial and independent peer review processes by the Grant Review Committee. This process will ensure that only the highest quality, most relevant and most competitive research is accepted but that it is.

The grants are supported by the financial contributions allocated by the sponsor, who, has no control, influence, or involvement in the selection process of the attendees whatsoever. Priority is given to applicants who have actively participated in original research or scientific work that is being presented at the meeting and/or those who will profit most from participating in order to improve their daily clinical management.

These grants help defray costs for registration, travel and accommodation for delegates and foster their ability to form valuable professional networks and develop vital collaborations. Conference participation grant applications will be solicited, selected and awarded by an expert Grant Review Committee.

Please note that the TITANIUM, PLATINUM and GOLD support levels will reduce the costs for conference participation grants. Supporters can indicate a desired number of CPGs to be granted in the response form further below.

ENDURING MATERIALS

INFECTIOUS DISEASES ONLINE

Enduring information presented at the conference will be freely retrievable and widely disseminated to reach thousands of virtual participants beyond the walls of the conference center. Infectious Diseases Online is a premier online platform offering scientific materials in special topical areas and proceedings of conferences. By accessing the website, visitors have full access to:

• Abstract Books
• Meeting Reports
• Workshop Presentations
• Webcasts

All the data on Infectious Diseases Online is organized by workshop and date, making the materials highly organized and easy to find.
COMMITTEES

ORGANIZING COMMITTEE

Charles Boucher, MD, PhD
Erasmus Medical Centre, the Netherlands

Francesca Ceccherini - Silberstein, PhD
University of Rome “Tor Vergata”, Italy

Stephane Chevaliez, PharmD, PhD
Hopital Henri Mondor, France

Andrea de Luca, MD
University of Siena, Italy

Stephan Dressler, MD, PhD
EATG, Germany

Anne - Genevieve Marcelin, PharmD, PhD
UPMC, France

Roger Paredes, MD, PhD
Irsi Caixa Foundation, Barcelona, Spain

Carlo Federico Perno, MD, PhD
University of Rome “Tor Vergata”, Rome, Italy

Jonathan Schapiro, MD
Sheba Medical Center, Israel

Anne - Mieke Vandamme, PhD
Katholieke Universiteit Leuven, Belgium

Linos Vandekerckhove, MD, PhD
University of Gent, Belgium

Jens Verheyen, MD, PhD
University of Toronto, Canada

Annemarie Wensing, MD, PhD
UMCU, the Netherlands
SCIENTIFIC COMMITTEE

Jan Albert, MD - IMPI Karolinska Institute, Sweden
Claudia Balotta, MD - University of Milan, Italy
Carlos Beltran, MD - Chilean AIDS Group, Chile
Marina Bobkova, PhD - Ivanovsky Institute of Virology, Russia
Ricardo Camacho, PhD - Hospital Egas Moniz, Portugal
Bonaventura Clotet, MD, PhD - Irsi Caixa Foundation, Barcelona, Spain
Rolf Kaiser, PhD - University of Cologne, Germany
Leon Kostrikis, PhD - University of Cyprus, Cyprus
Clive Loveday, PhD - ICVC Charitable Trust, Clinical Virology, United Kingdom
Jens Lundgren, MD - National University Hospital & University of Copenhagen, Denmark
Anne-Genevieve Marcelin, PharmD, PhD - UPMC, France
Claus Nielsen, MD, PhD - Statens Serum Institut, Denmark
Monique Nijhuis, PhD - University Medical Center Utrecht, The Netherlands
Dimitris Paraskevis, PhD - University of Athens, Medical School, Greece
Mario Poljak, MD, PhD - Institute for Microbiology and Immunology, Slovenia
Elisabeth Puchhammer, MD - University of Vienna, Austria
Jürgen Rockstroh, MD - University of Bonn, Germany
Christophe Rodriguez, MD - Hôpital Henri Mondor, France
Gary Rubin, MD - University of Toronto, Canada
Jean-Claude Schmit, MD, PhD - Centre Hospitalier de Luxembourg & CRP-Santé, Luxembourg
Rob Schuurman, PhD - University Medical Centre Utrecht, The Netherlands
Anders Sönnerborg, MD, PhD - Karolinska Institut, Sweden
Vincent Soriano, MD, PhD - Hospital Carlos III, Spain
Janusz Stanczak, PhD - University of Warsaw, Poland
Adrian Streinu-Cercel, MD, PhD - National Institute of Inf. Diseases “Prof.Dr. Matei Bals”, Romania
Hauke Walter, MD - Medizinisches Labor Dr. Berg, Germany
Maurizio Zazzi, PhD - University of Siena, Italy
Fabien Zoulim, MD, PhD - INSERM, France
# ACKNOWLEDGEMENTS

## PREVIOUS SUPPORTERS

<table>
<thead>
<tr>
<th>Company/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViiV Healthcare</td>
</tr>
<tr>
<td>Gilead</td>
</tr>
<tr>
<td>AbbVie</td>
</tr>
<tr>
<td>Janssen</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>MSD Be well</td>
</tr>
<tr>
<td>Roche</td>
</tr>
<tr>
<td>Siemens</td>
</tr>
<tr>
<td>Monogram Biosciences</td>
</tr>
<tr>
<td>Covance</td>
</tr>
</tbody>
</table>

## ENDORSERS

<table>
<thead>
<tr>
<th>Endorser</th>
</tr>
</thead>
<tbody>
<tr>
<td>European Society of Microbiology and Infectious Diseases (ESCMID)</td>
</tr>
<tr>
<td>Italian Society for Virology (SIV-ISV-SV)</td>
</tr>
<tr>
<td>AIDS Treatment Group (EATG)</td>
</tr>
</tbody>
</table>

## ACADEMIC PARTNERS

<table>
<thead>
<tr>
<th>University</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of Bologna (ULB)</td>
</tr>
<tr>
<td>KU Leuven</td>
</tr>
<tr>
<td>Institute of Infection and Global Health (Liverpool)</td>
</tr>
<tr>
<td>Germans Trias i Pujol Hospital</td>
</tr>
<tr>
<td>IrsiCaixa</td>
</tr>
<tr>
<td>Statens Serum Institut</td>
</tr>
</tbody>
</table>

---

European Meeting on HIV & Hepatitis: Treatment Strategies & Antiviral Drug Resistance 2018 - Meeting Prospectus
FOR MORE INFORMATION, PLEASE CONTACT US AT:

VIROLOGY EDUCATION
Biltstraat 106
3572 BJ Utrecht
the Netherlands

www.virology-education.com
info@virology-education.com
+31 30 230 7146